{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:25:15Z","timestamp":1793982315818,"version":"4.8.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rituximab-induced serum sickness (RISS) is an uncommon delayed hypersensitivity reaction with incompletely characterized clinical features and management. We aimed to synthesize published case reports\/series to delineate clinical patterns, therapeutic strategies, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE, Web of Science, WanFang Data, and China National Knowledge Infrastructure (CNKI) were searched for rituximab-induced serum sickness reports published up to Nov 31, 2025, using keywords and free-text terms (e.g., \u201cRituximab,\u201d \u201cSerum Sickness,\u201d \u201cSerum Sickness-Like Reaction,\u201d \u201cHypersensitivity,\u201d \u201cAdverse Drug Reaction,\u201d \u201cRISS,\u201d and \u201canti-CD20\u201d) with Boolean operators. Eligible case reports\/series were screened and data were extracted with a standardized form. Study quality was evaluated using the JBI Critical Appraisal Checklist for Case Reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>30 eligible articles identified 39 patients. The median age was 33 years (range 6, 86), with a female predominance (71.8%). The median symptom onset time was 7 days (range 1, 18) after last rituximab exposure. The most common indications were multiple sclerosis (23.1%), nephrotic syndrome (20.5%), and immune thrombocytopenia (20.5%). Clinically, arthralgia\/arthritis (92.3%), fever (82.1%), and rash (66.7%) predominated. Anti-rituximab antibodies were positive in 90.9% of tested cases. Inflammatory markers were frequently elevated, with 93.3% of patients showing elevated erythrocyte sedimentation rate (ESR) and 91.3% showing elevated C-reactive protein (CRP). Complement consumption were frequent, with decreased C3 and C4 levels observed in 76.5% and 78.6% of tested patients, respectively. Corticosteroids were commonly used as the treatment for RISS, while switching to another anti-CD20 agent was primarily a strategy for managing the underlying disease. Overall, 82.1% achieved complete recovery and 15.4% improved, with a median recovery time of 3.0 days. Rechallenge was reported in 10 patients, with recurrence in 60.0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RISS is a delayed reaction occurring after a free interval of several days, but it may clinically present shortly after a subsequent infusion in repeated dosing regimens. Its main features include the classic triad of fever, rash, and arthralgia or arthritis, commonly accompanied by elevated inflammatory markers and hypocomplementemia. Most patients improve rapidly after drug withdrawal, supportive care, and short-course corticosteroid therapy; however, rechallenge carries a substantial risk of recurrence and should be approached cautiously.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1798283","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:47:51Z","timestamp":1776059271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan University)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan University)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hunan University of Medicine General Hospital","place":["Huaihua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan University)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine","place":["Zhongshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013874.pub3","article-title":"Rituximab for people with multiple sclerosis","volume":"3","author":"Filippini","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014574.pub2","article-title":"Rituximab for myasthenia gravis","volume":"7","author":"Dodd","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae084","article-title":"Rituximab or cyclosporine a for the treatment of membranous nephropathy: economic evaluation of the mentor trial","volume":"39","author":"Kadatz","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08878-x","article-title":"Immediate and delayed hypersensitivity reactions to antibiotics: aminoglycosides, clindamycin, linezolid, and metronidazole","volume":"62","author":"Dilley","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.02.027","article-title":"Serum sickness-like reactions clinical characteristics and management: a systematic review","volume":"13","author":"Khalaf","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","article-title":"Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological Malignancies: a French nationwide study","volume":"67","author":"Bayer","year":"2019","journal-title":"Eur J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38333","article-title":"Rituximab-induced serum sickness overlapping with anaphylaxis: a case report","volume":"15","author":"Cottu","year":"2023","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-06703-7","article-title":"Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies","volume":"40","author":"Fujinaga","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863177","article-title":"Case report: Use of obinutuzumab as an alternative monoclonal anti-cd20 antibody in a patient with refractory immune thrombocytopenia complicated by rituximab-induced serum sickness and anti-rituximab antibodies","volume":"13","author":"Blase","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20231019-00304","article-title":"Two cases of rituximab induced serum sickness in children with nephrotic syndrome","volume":"62","author":"Yang","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/annonc\/mdg488","article-title":"Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment","volume":"14","author":"Hellerstedt","year":"2003","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2174\/1574886309666140509154056","article-title":"Desensitization protocol for rituximab-induced serum sickness","volume":"9","author":"Fajt","year":"2014","journal-title":"Curr Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000262585.18582.1e","article-title":"Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia","volume":"13","author":"Finger","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.11.003","article-title":"Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: a case report","volume":"177","author":"Joubert","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03635.x","article-title":"Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura","volume":"52","author":"Bhagirath","year":"2012","journal-title":"Transfusion"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2020.05.025","article-title":"Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome","volume":"62","author":"Bayram","year":"2020","journal-title":"Turk J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00449-x","article-title":"Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome","volume":"9","author":"Nakamura","year":"2020","journal-title":"CEN Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-022-00709-y","article-title":"Rituximab-induced serum sickness in a girl with nephrotic syndrome","volume":"11","author":"Kimura","year":"2022","journal-title":"CEN Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701441752","article-title":"Rituximab-induced serum sickness in a patient with follicular lymphoma","volume":"48","author":"Disperati","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88465","article-title":"Rituximab-induced serum sickness in a seven-year-old child with nephrotic syndrome","volume":"17","author":"Mauvezin","year":"2025","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9152","article-title":"Rituximab-induced serum sickness in immunobullous disorders: a case series","volume":"12","author":"Gheisari","year":"2024","journal-title":"Clin Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.04.010","article-title":"Rituximab-induced serum sickness in lymphoma: a case report","volume":"21","author":"Navarro-Matilla","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101402","article-title":"Rituximab-induced serum sickness in multiple sclerosis patients","volume":"36","author":"Wolf","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13256-025-05222-1","article-title":"Rituximab-induced serum sickness in progressive transformation of germinal centers immunoglobulin g4-related disease: a case report","volume":"19","author":"Kumar","year":"2025","journal-title":"J Med Case Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2010.02384.x","article-title":"Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura","volume":"41","author":"Le Guenno","year":"2011","journal-title":"Intern Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ajh.10127","article-title":"Rituximab-induced serum sickness","volume":"70","author":"Herishanu","year":"2002","journal-title":"Am J Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/dad.0000000000000356","article-title":"Rituximab-induced serum sickness-like reaction: a histopathologic viewpoint","volume":"38","author":"Succaria","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01645.x","article-title":"Serum sickness and severe angioedema following rituximab therapy in ra","volume":"15","author":"Kumar","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/rheumatology\/keh470","article-title":"Serum sickness associated with rituximab in a patient with hepatitis c virus-related mixed cryoglobulinaemia","volume":"44","author":"Catuogno","year":"2005","journal-title":"Rheumatol (Oxford)"},{"key":"B34","first-page":"967","article-title":"Serum sickness following a first rituximab infusion with no recurrence after the second one","volume":"26","author":"Mehsen","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3642","article-title":"Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: a case report","volume":"9","author":"Khatib","year":"2021","journal-title":"Clin Case Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e3181596652","article-title":"Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan","volume":"32","author":"DeMonaco","year":"2007","journal-title":"Clin Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1717::Aid-art299>3.0.Co;2-c","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody idec-c2b8 (rituximab)","volume":"44","author":"D\u2019Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0269-6","article-title":"Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura","volume":"89","author":"Goto","year":"2009","journal-title":"Int J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00492-8","article-title":"The case of kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies","volume":"9","author":"Sato","year":"2020","journal-title":"CEN Case Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000000685","article-title":"Serum sickness following rituximab therapy in multiple sclerosis","volume":"9","author":"Holm\u00f8y","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5\u2009years from the French prospective registry itp-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx072","article-title":"Rituximab-induced serum sickness in the treatment of\u00a0idiopathic membranous nephropathy","volume":"11","author":"Cheong","year":"2018","journal-title":"Clin Kidney J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520910486","article-title":"A possible case of serum sickness after ocrelizumab infusion","volume":"27","author":"Moreira Ferreira","year":"2021","journal-title":"Mult Scler"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15177","article-title":"Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies","volume":"184","author":"Vendramin","year":"2019","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1798283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:47:53Z","timestamp":1776059273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1798283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1798283"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1798283","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1798283"}}